<DOC>
	<DOCNO>NCT00550992</DOCNO>
	<brief_summary>RATIONALE : Giving chemotherapy donor stem cell transplant help stop growth cancer cell . It also help stop patient 's immune system reject donor 's stem cell . When healthy stem cell donor infused patient may help patient 's bone marrow make stem cell , red blood cell , white blood cell , platelet . Sometimes transplanted cell donor make immune response body 's normal cell . Giving cyclosporine , methotrexate , leucovorin , antithymocyte globulin transplant may stop happen . It yet know treatment regimen effective treat acute leukemia . PURPOSE : This randomized clinical trial study well different therapy work treat infant newly diagnose acute leukemia .</brief_summary>
	<brief_title>Different Therapies Treating Infants With Newly Diagnosed Acute Leukemia</brief_title>
	<detailed_description>OBJECTIVES : Primary - To compare early intensification regimen comprise two `` acute myeloid leukemia '' induction therapy block standard protocol IB regimen administer directly induction therapy medium-risk ( MR ) high-risk ( HR ) patient newly diagnose acute lymphoblastic biphenotypic leukemia . Secondary - To compare randomize study role regimen treat patient . - To compare overall outcome Interfant-06 study outcomes historical control series , especially Interfant-99 study . - To compare outcomes low-risk , MR , HR patient study patient historical control series Interfant-99 study . - To study factor independent prognostic value patient treat regimen . - To assess role stem cell transplantation HR patient . OUTLINE : This multicenter study . - Induction therapy : - Prednisone phase : Patients receive prednisone orally IV three time daily day 1-7 methotrexate ( MTX ) prednisolone ( PRDL ) intrathecally ( IT ) day 1 . Patients proceed remission induction therapy . - Remission induction phase : Patients receive dexamethasone ( DEXA ) IV orally three time daily day 8-28 follow taper 0 1 week ; vincristine ( VCR ) IV day 8 , 15 , 22 , 29 ; cytarabine ( ARA-C ) IV 30 minute day 8-21 ; daunorubicin hydrochloride ( DNR ) IV 1 hour day 8 9 ; asparaginase ( ASP ) IV 1 hour intramuscularly ( IM ) day 15 , 18 , 22 , 25 , 29 , 33 ; MTX IT day 1 29* ; ARA-C IT day 15 . Patients also receive PRDL therapeutic hydrocortisone ( HC ) IT day 1 , 15 , 29 . NOTE : *Patients CNS involvement initial diagnosis also receive MTX IT day 8 22 . If CNS leukemia still present day 29 , patient receive weekly MTX IT CNS free leukemia . After completion induction therapy , patient stratify accord risk group ( low-risk [ LR ] v medium-risk [ MR ] v high-risk [ HR ] ) . Patients low-risk disease assign treatment arm I . Patients MR HR disease complete remission ( CR ) day 33 randomize 1 2 treatment arm . These patient stratify accord status ( MR rearrange MLL v MR unknown MLL v HR ) . - Arm I ( standard therapy ) : - Protocol IB therapy ( begin day 36 induction therapy ) : Patients receive cyclophosphamide ( CPM ) IV 1 hour day 1 29 oral mercaptopurine ( MP ) day 1-28 ; ARA-C IV day 3-6 , 10-13 , 17-20 , 24-27 ; ARA-C IT day 10 ; MTX IT day 24 . Patients also receive PRDL therapeutic HC IT day 10 24 . - MARMA therapy : - Part I : Patients receive oral MP daily day 1-14 ; high-dose ( HD ) MTX IV 24 hour day 1 8 ; leucovorin calcium orally IV 42 , 48 , 54 hour dose MTX MTX plasma level safe ; MTX IT day 2 9 . Patients also receive PRDL therapeutic HC IT day 2 9 . - Part II : Patients receive HD ARA-C IV 3 hour twice daily 12-hour interval day 15 , 16 , 22 , 23 ; pegaspargase ( PEG-ASP ) IV 1 hour IM day 23 . - OCTADA ( D ) reinduction therapy : - Part I : At least 2 week completion MARMA chemotherapy , patient receive oral dexamethasone ( DEXA ) three time daily day 1-14 , follow taper 0 day 21 ; oral thioguanine ( TG ) daily day 1-28 ; VCR IV day 1 , 8 , 15 , 22 ; DNR IV 1 hour day 1 , 8 , 15 , 22 ; PEG-ASP IV 1 hour IM day 1 ; ARA-C IV day 2-5 , 9-12 , 16-19 , 23-26 ; ARA-C IT day 1 15 . Patients also receive PRDL therapeutic HC IT day 1 15 . - Part II : Patients receive oral TG daily day 36-49 ; ARA-C IV daily day 37-40 45-48 ; CPM IV 1 hour day 36 49 . - Maintenance therapy : At least 2 week completion last course OCTADA ( D ) chemotherapy , patient receive oral MP daily ; oral MTX weekly ; MTX IT week 1 15 ; ARA-C IT week 8 . Patients also receive PRDL therapeutic HC IT week 1 , 8 , 15 . Treatment continue 104 week initial diagnosis absence disease progression unacceptable toxicity . - Arm II ( experimental therapy ) : - ADE therapy ( begin day 36 induction therapy : Patients receive ARA-C IV every 12 hour day 1-10 ; DNR IV 1 hour day 1 , 3 , 5 ; etoposide ( VP-16 ) IV 4 hour day 1-5 ; ARA-C IT day 1 . Patients also receive PRDL therapeutic HC IT day 1 . - MAE therapy : Patients receive ARA-C IV every 12 hour day 1-10 ; mitoxantrone hydrochloride IV 1 hour day 1 , 3 , 5 ; VP-16 IV 4 hour day 1-5 ; MTX IT day 1 . Patients also receive PRDL therapeutic HC IT day 1 . - MARMA therapy : - Part I : Patients receive oral MP daily day 1-14 ; high-dose ( HD ) MTX IV 24 hour day 1 8 ; leucovorin calcium orally IV 42 , 48 , 54 hour dose MTX MTX plasma level safe ; MTX IT day 2 9 . Patients also receive PRDL therapeutic HC IT day 2 9 . - Part II : Patients receive HD ARA-C IV 3 hour twice daily 12-hour interval day 15 , 16 , 22 , 23 ; pegaspargase ( PEG-ASP ) IV 1 hour IM day 23 . - OCTADA reinduction therapy : - Part I : At least 2 week completion MARMA chemotherapy , patient receive oral DEXA three time daily day 1-14 , follow taper 0 day 21 ; oral TG daily day 1-28 ; VCR IV day 1 , 8 , 15 , 22 ; PEG-ASP IV 1 hour IM day 1 ; ARA-C IV day 2-5 , 9-12 , 16-19 , 23-26 ; ARA-C IT day 1 15 . Patients also receive PRDL therapeutic HC IT day 1 15 . - Part II : Beginning 1 week completion part I , patient receive oral TG daily day 36-49 ; ARA-C IV daily day 37-40 45-48 ; CPM IV 1 hour day 36 49 . - Maintenance therapy : At least 2 week completion last course OCTADA chemotherapy , patient receive oral MP daily ; oral MTX weekly ; MTX IT week 1 15 ; ARA-C IT week 8 . Patients also receive PRDL therapeutic HC IT week 1 , 8 , 15 . Treatment continue 104 week initial diagnosis absence disease progression unacceptable toxicity . All HR patient suitably match donor schedule allogeneic stem cell transplantation ( SCT ) MARMA OCTADA ( D ) chemotherapy , provide CR1 8 month elapse since initial diagnosis . - Conditioning regimen allogeneic SCT : - Matched sibling donor ( MSD ) : Patients receive oral busulfan ( BU ) every 6 hour day -7 -4 ; CPM IV 1 hour day -3 -2 ; melphalan ( MEL ) IV 1 hour day -1 . - Matched donor ( MD ) : Patients receive oral BU every 6 hour day -7 -4 ; CPM IV 1 hour day -3 -2 ; MEL IV 1 hour day -1 ; anti-thymocyte globulin ( ATG ) IV 4 hour day -3 -1 . - Graft-Versus-Host Disease ( GVHD ) prophylaxis therapy : - MSD : Patients receive cyclosporine ( CsA ) IV orally twice daily begin day -1 continue day 60 SCT , follow taper absence GVHD symptom . - MD : Patients receive CsA group MSD ; MTX IV day 1 , 3 , 6 ; leucovorin calcium IV day 2 , 4 , 7 ; ATG IV day -3 -1 . - Allogeneic SCT : Patients undergo infusion bone marrow , peripheral blood , cord blood hematopoietic stem cell day 0 . After completion study therapy , patient follow periodically 2 year .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>6-Mercaptopurine</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Pegaspargase</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<mesh_term>Asparaginase</mesh_term>
	<mesh_term>Mitoxantrone</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Thioguanine</mesh_term>
	<mesh_term>Hydrocortisone 17-butyrate 21-propionate</mesh_term>
	<mesh_term>Cortisol succinate</mesh_term>
	<mesh_term>Hydrocortisone acetate</mesh_term>
	<mesh_term>Hydrocortisone</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Inclusion criterion : Diagnosis acute lymphoblastic leukemia ( ALL ) biphenotypic leukemia meeting follow criterion : Based European Group Classification Acute Leukemia ( EGIL ) diagnostic criterion Newly diagnose disease Verified morphology confirm cytochemistry immunophenotyping Trephine biopsy recommend ( unless diagnosis confirm peripheral blood examination ) event bone marrow aspiration result `` dry tap '' Must MLL gene rearrangement document splitsignal fluorescence situ hybridization meet 1 follow risk criterion : Lowrisk disease , define MLL germline case Mediumrisk disease , define 1 follow criterion : MLL status unknown MLL rearrange AND age &gt; 6 month MLL rearrange AND age &lt; 6 month AND WBC &lt; 300 x 10^9/L AND prednisone good response Highrisk disease , define MLL rearrangement AND meet follow criterion : Age diagnosis &lt; 6 month ( i.e. , &lt; 183 day ) WBC ≥ 300 x 10^9/L AND/OR prednisone poor response Minimum donor stem cell requirement highrisk patient undergo stem cell transplantation : Donor meet 1 follow criterion : HLAidentical sibling Very wellmatched relate unrelated donor Must HLA compatible 10/10 9/10 allele 4 digit/allele highresolution molecular genotyping Stem cell source Bone marrow ( prefer source ) OR peripheral blood stem cell filgrastim [ GCSF ] stimulate donor OR cord blood Highlymatched unrelated umbilical cord blood ( UCB ) ( &gt; 7/8 match identify highresolution type ) accept sibling donor able donate bone marrow AND UCB sufficient number nucleate cell ( NCs ) ( i.e. , &gt; 1.5 x 10^7/kg recipient body weight [ BW ] ) cryopreserved Must ≥ 3 x 10^8 NCs/kg BW OR 3 x 10^6/kg BW CD34positive cell available transplantation CNS testicular leukemia diagnosis allow Exclusion criterion : Mature BALL , define immunophenotypical presence surface immunoglobulin ( 8 ; 14 ) breakpoint BALL Presence ( 9 ; 22 ) ( q34 ; q11 ) bcrabl fusion leukemic cell ( data know , patient still may eligible ) Relapsed ALL PATIENT CHARACTERISTICS : See Disease Characteristics PRIOR CONCURRENT THERAPY : More 4 week since prior systemic corticosteroid Corticosteroids aerosol allow</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>1 Year</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>untreated childhood acute lymphoblastic leukemia</keyword>
	<keyword>T-cell childhood acute lymphoblastic leukemia</keyword>
	<keyword>acute undifferentiated leukemia</keyword>
</DOC>